1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hoth Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel - Acneiform Eruption Due to Chemical, Xerosis Cutis | Phase 2 | Recruiting | Hoth Therapeutics, Inc. | 152 | 2023-07-19 | 2026-03-31 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis BioLexa- Cohort 1, BioLexa- Cohort 2, Placebo - Atopic Dermatitis | Phase 1 | Completed | Hoth Therapeutics, Inc. | 31 | 2021-05-17 | 2022-11-17 |
Dermatitis, Atopic (1) · Paronychia (1)
Gels (1) · Gentamicins (1)
Australia (1) · Poland (1) · Spain (1) · United States (1)
Mario Lacouture, MD (1) · Oscar Cumming, Dr (1)